Drug Metabolism and Personalized Therapy
Official journal of the European Society of Pharmacogenomics and Personalised Therapy
Editor-in-Chief: Siest, Gérard / Llerena, Adrián
Editorial Board Member: Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Henney, Adriano / Hirata, Rosario D. C. / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van de Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Sadee, Wolfgang / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Visvikis-Siest, Sophie / Zanger, Ulrich M.
4 Issues per year
SCImago Journal Rank (SJR): 0.366
Source Normalized Impact per Paper (SNIP): 0.500
Volume 30 (2015)
Volume 29 (2014)
Volume 28 (2013)
Volume 27 (2012)
Volume 26 (2011)
Volume 25 (2010)
Volume 22 (2007)
Volume 21 (2006)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2001)
Volume 16 (2000)
Volume 17 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1995)
Volume 11 (1994)
Volume 10 (1992)
Volume 9 (1991)
Volume 8 (1990)
Volume 5 (1987)
Volume 4 (1982)
Most Downloaded Articles
- Congress Abstracts*/Second ESPT Conference “Pharmacogenomics: From Cell to Clinic”
- 6th Santorini Conference Biologie Prospective 2012
- Lurasidone drug-drug interaction studies: a comprehensive review by Chiu, Yu-Yuan/ Ereshefsky, Larry/ Preskorn, Sheldon H./ Poola, Nagaraju and Loebel, Antony
- European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies: the 2012 Declaration of Rome by Brand, Angela and Lal, Jonathan A.
Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review
1Pharmacy Department, Torrecárdenas Hospital, Almería, Spain
2Infectious Diseases Unit, Torrecárdenas Hospital, Almería, Spain
3The Arnold and Marie Schwartz School of Pharmacy, Long Island University, New York, USA
4Pharmacy Department, The Mount Sinai Medical Center, New York, USA
Citation Information: . Volume 27, Issue 3, Pages 171–175, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: 10.1515/dmdi-2012-0019, July 2012
- Published Online:
Background: In the last decade, some evidence has arisen supporting the usefulness of Asian ginseng (Panax ginseng, fam. Araliaceae) as a complementary remedy in patients receiving antiretroviral therapy. However, its role in current therapeutics remains unclear.
Methods: The patient was admitted for an acute elevation of liver enzymes, marked jaundice, and significant weight loss after taking ginseng-based tablets starting approximately 39 days prior. His past medical history (PMH) was also significant for HIV+, long-term hepatitis C, an episode of mitochondrial toxicity, and several comorbidities. His outpatient medications included raltegravir 400 mg plus lopinavir/ritonavir 400/100 mg twice daily, aspirin 100 mg daily, and esomeprazole 40 mg daily as needed.
Results: The cessation of the ginseng lozenges led to a progressive improvement in the performance status and laboratory values. Both the Hansten and Horn nomogram and the Roussel Uclaf Causality Assessment Method indicated that the association between the ginseng medicine and the liver injury was probable (six points).
Conclusions: We suggest that ginseng is involved in the episode through an interaction resulting in elevated plasma concentrations of raltegravir. As a consequence, clinicians should be alert when managing patients on other CYP3A4-metabolized drugs or previous liver-damaging conditions. However, larger studies are required to explicitly clarify these statements.